Dra. Ana Aparicio
MD Anderson Cancer Center Houston, Houston, Texas
Dr. Aparicio has focused her research efforts on characterizing a clinically distinct subset of the advanced prostate cancer disease, the aggressive variant prostate cancers, which is estimated to constitute up to one third of the disease. She believes that her ongoing research will ultimately enhance the care she is able to provide to her clinical patients and to those in the community afflicted with the same disease.
Hospital Universitari i Politècnic la Fe, Valencia
Jefe de Sección (unidad de tumores digestivos y musculoesqueléticos) en el Hospital Universitario y Politécnico La Fe, Valencia.
Miembro actual de la Junta Directiva de la Sociedad Española de Oncología Médica (SEOM).
También miembro de las sociedades científicas European Society of Medical Oncology (ESMO) y American Society of Clinical Oncology (ASCO), así como de los grupos cooperativos Grupo Español para el Estudio y Tratamiento de los Tumores Digestivos (TTD), Grupo Español de Tumores Germinales (GG) y Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD)
Investigador principal en más de 70 ensayos clínicos, autor de más de 120 ponencias o conferencias en reuniones científicas y autor de más de 80 artículos en revistas internacionales de oncología.
The Institute of Cancer Research and the Royal Marsden, Shutton, UK
Dr. Álvaro Aytes
Institut Català d’Oncologia, Barcelona
Dr. Joaquim Bellmunt
Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
His areas of interest in genitourinary oncology include the development of drugs directed to novel therapeutic targets and early clinical and translational research in the field of growth factor receptors and angiogenesis. While his research interests are focused on bladder cancer, he has extensive experience treating prostate, penile and kidney cancer. He serves on International committees focused on improving the treatments of genitourinary and bladder cancers. He is a member of the Editorial Board of the Journal of Clinical Oncology and European Urology.
He has been chairing two of the larger multicenter international trials of new drugs in the treatment of bladder cancer, in one of them, leading to the establishment of a new drug for bladder cancer patients. Dr. Bellmunt’s research focuses on clinical trials with aims to improve the treatment of patients with advanced bladder (urothelial) tumors as well as the development of novel agents for this disease. Dr. Bellmunt is currently involved in collaborative efforts with basic scientists to analyze clinical, tissue, and biomarkers to optimize the administration of targeted therapeutic agents in bladder cancer.
Hospital Universitario Zürich, Zürich
1989-1999 Postgraduate Training, Charité University, Berlin Germany
1999-2005 Associate Professor, University of Marburg, Germany,
2005-2007 Medical Director, Community Hospital Network, Ravensburg, Germany
2007-2013 Head of Department, Vivantes Klinikum Am Urban, Berlin, Germany
Since 2013 Consultant Oncologist, University Hospital Zurich, Switzerland
Main Research Interest
Since September 2013 I serve as a consultant at the department of oncology at the University Hospital Zurich. Apart from teaching activities in the local curriculum, my clinical focus is on lymphomas, sarcomas and urogenital tumors with medical ethics as another special interest. I am also affiliated and teach at the Wilsede School of Oncology in Germany, the European School of Oncology and at seminars of the European Society of Medical Oncology in addition to presentations and educationals at international congresses.
Between 1982 and 1989 I received my medical training at the Free University Berlin, Germany, at the Royal Free Hospital in London, UK, and the Brown University in Rhode Island, US. My postgraduate medical training in internal medicine, hematology, oncology and palliative care took place at the Charité University Hospital, Berlin, Germany, between 1989 and 1999. From 1999 until 2005 I held a post as associate professor at the University Hospital in Marburg, Germany. From 2005 until 2007 I was appointed medical director at a community hospital in Ravensburg, Germany, and from 2007 until 2013 I was head of the department of hematology and oncology at the Vivantes Klinikum Am Urban in Berlin, Germany, and director of the Vivantes Cancer Center.
I am author and co-author of more than 160 original articles, reviews and book chapters.
Dr. James Brugarolas
University of Texas, Texas, USA
Hospital Universitario Virgen del Rocío, Sevilla
Tras su formación clínica en el Hospital Clínico Universitario de Son Dureta (Palma de Mallorca), trabajó en el Servicio de Oncología Médica del Hospital Universitario Doce de Octubre (Madrid) y durante el trienio 2004-2007 en los departamentos de Desarrollo de Nuevos Fármacos y de Tumores Genitourinarios del “Princess Margaret Hospital” de Toronto (Ontario, Canadá).
Durante su estancia en Toronto completo un programa de Máster de docencia orientada a la medicina en la Universidad de Toronto. Es autor de importantes trabajos en diferentes ámbitos de la oncología médica publicados en destacadas revistas científicas. A lo largo de su carrera ha recibido entre otros galardones, el ASCO Foundation Merit Award, el Novartis Young Canadian Investigator Award y el University Health Network Outstanding Research Presentation Award.
Dr. Karim Fizazi
Institute Gustave-Roussy, Villejuif, France
- September 2009: Full Professor, Institut Gustave Roussy, University of Paris, France.
- Since June 2005: Appointed Head of the Department of Medicine, Institut Gustave Roussy (IGR), France.
- Since 2004: Chairman of the Genito-urinary Oncology Group, Institut Gustave Roussy (IGR), France.
- Since 2001: Assistant Professor in Medical Oncology, Department of Medicine, Institut Gustave Roussy (IGR), France.
- 1999-2001: Visiting Assistant Professor, Genitourinary Medical Oncology Department, MD Anderson cancer Center, Houston, TX, USA.
- 1997-1999: Assistant Professor in Medical Oncology, department of Medicine, Institut Gustave Roussy (IGR), France.
- 1995-1997: Appointed Chef de clinique (Fellow) Medical oncology, Institut Gustave Roussy (IGR), France.
- 1991-1995: Appointed Interne des hôpitaux de Paris (Residency):
- Medical Oncology, Department of Pr Marty, Hôpital St Louis (1995)
- Medical Oncology, Department of Pr Droz and Dr Le Chevalier, IGR (1995)
- Medical Oncology, Department of Pr Pouillart, Institut Curie (1993)
- Medical Oncology, Department of Pr Tursz, IGR (1993)
- Radiotherapy, Department of Pr Cosset, Institut Curie (1992)
- Medical Oncology, Department of Dr Ruffié, IGR (1992)
- Cardiology, Department of Pr Leca, Hôpital Laënnec (1991)
- Emergency, Department of Dr Duliouste, La Rochelle (1991)
- 1994: Diplôme d’Etudes Appliquées: Postgraduate Diploma prior to PhD, Fundamental Bases of Oncogenesis, Pr Tursz’ Laboratory, IGR
MEDICAL AND SCIENTIFIC QUALIFICATIONS
- 2003: Ph.D. (Molecular Oncology)
- 1997: « Ancien Chef de Clinique » (Fellowship), Medical Oncology
- 1995: MD (Medical Oncology)
- 1990: Concours de l’Internat de Paris (Competitive Examination) ranked 45 / 3000 candidates, Internal Medicine.
- October 1984 to June 1990: Medical school, University of Poitiers, France
Corporació Sanitària Parc Taulí, Sabadell, Barcelona
He was Attending at Oncology Department at Vall d’Hebron Hospital in 1996 and Clinical Trials Coordinator in the same department between 1996 and 1999, later to be Attending at Oncology Service at Terrassa Hospital in Barcelona until 2002. He is currently Senior Attending Physician at Oncology Department at Corporació Parc Taulí in Sabadell, Barcelona, and responsible for the Uro-Oncology Unit.
He is a member of the Spanish Group for treatment of Genito-Urinary Tumors (SOGUG) where is actively involved in Kidney Cancer and Bladder Cancer Working Groups. He is an active member of the SEOM (Spanish Society of Medical Oncology), ESMO (European Society of Medical Oncology), ASCO (American Society of Clinical Oncology), IASLC (International Association for the Study of Lung Cancer) and EORTC (European Organisation for the Research and Treatment of Cancer), Genito-Urinary Cancer Group.
He has participated as a researcher and designer in many clinical trials in various areas of oncology, especially in urological tumors, including phase I, II, II and IV trials. He has participated in the development of Prostate Cancer OncoGuide in Catalonia and SOGUG Kidney Cancer and Bladder Cancer Guides. He has published around 100 articles, book chapters and communications at national and international meetings.
His areas of expertise include the treatment of urological tumors (kidney, urothelial carcinomas, prostate and germ-cell tumors) and central nervous system neoplasms. He is also interested of other cancer-related areas, such as cancer-related thrombosis and supportive care.
Dr. Jorge García
Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio
Dr. Garcia earned his medical degree at the Colombian School of Medicine in Bogota, Colombia (South America). After completing a Cancer Biology Fellowship at Harvard Medical School, Dr. Garcia completed his training in Internal Medicine at the Albert Einstein College of Medicine in New York. Subsequently, Dr. Garcia was awarded a fellowship in hematology and oncology and Urologic Oncology at the University of California San Francisco.
Certified in Medical Oncology and Internal Medicine by the American Board of Internal Medicine, Dr. Garcia’s primary research at the Cleveland Clinic has been in prostate, kidney and bladder cancer, with special focus on developmental therapeutics and targeted therapy. Dr. Garcia’s has authored over 100 manuscripts and his research has been published in peer-reviewed journals that include New England Journal of Medicine, Clinical Cancer Research, Journal of Clinical Oncology, Journal of the National Cancer Institute, Lancet Oncology, Journal of Urology, Cancer and BJU International among others. He is a reviewer for several medical journals including, Clinical Cancer Research, Cancer, Urology, Annals of Oncology, Journal of Clinical Oncology, Clinical and Experimental Medicine and the BJU.
Dr. Garcia is a Fellow of the American College of Physicians and serves as a relevance reviewer for the American Board of Internal Medicine. He is also an editor for Urologic Oncology for the American Society of Clinical Oncology (ASCO) and currently serves as the Chair of the Scientific Protocol Review Committee at the Comprehensive Cancer Center at Case Western Reserve University. Dr. Garcia has also been listed among the best doctors in Cleveland and the United Stated every year since 2009.
Dr. Roberto García-Figueiras
Hospital Clínico Universitario, Santiago de Compostela
Hospital: COMPLEXO HOSPITALARIO UNIVERSITARIO DE SANTIAGO DE COMPOSTELA
Dept.: DEPARTMENT OF RADIOLOGY
Main Research Field
PhD in the field of FUNCTIONAL AND MOLECULAR IMAGING applied to Oncology (2014): “Valor de las técnicas de imagen funcional y molecular en los tumores” (“The Value of Functional and Molecular Imaging in Tumors”). Qualification: CUM LAUDE
- 6 books chapters published devoted to oncologic imaging
- 17 papers published devoted to oncologic imaging + other 34 radiological papers
- Speaker in many meetings mainly focused on oncologic imaging
- 12 national and international prizes in main radiological meetings
- International Meetings: 64 posters presented
- National Meetings: 53 posters presented
Dr. Enrique González Billalabeitia
Hospital General Universitario Morales Meseguer, Murcia
Dra. Aránzazu González del Alba
Hospital Universitario Son Espases, Mallorca
She completed her training in Clinical Oncology in Son Dureta University Hospital (Palma de Mallorca, 1994-1997) and holds a Master in Molecular Oncology: Molecular bases of Cancer. Molecular Pathology Program of the National Oncological Research Centre (CNIO), recognized by the European School of Oncology (2007-2009).
She is a staff physician of the Department of Clinical Oncology of Son Espases Universitary Hospital and since 2002 she has directed the Unit of Urological and Gynecological tumors.
Since 2009 she forms part of the Steering Committee of the Spanish Oncology Genitourinary Group (SOGUG), coordinating the Teaching Commission.
Dr. Enrique Grande
Hospital Universitario Ramón y Cajal, Madrid
Dr. Pablo Maroto
Hospital de la Santa Creu i Sant Pau, Barcelona
Dr. Joaquín Mateo
The Royal Marsden NHS Foundation Trust, London, UK
Dr. Sumanta Kumar Pal
City of Hope, California, USA
Assistant Professor, Department of Medical Oncology & Therapeutics Research
Co-director, Kidney Cancer Program
Sumanta Kumar Pal, M.D., is an assistant professor in the Department of Medical Oncology & Therapeutics Research and co-director of the Kidney Cancer Program at City of Hope. Having been appointed to the faculty for just over four years, Dr. Pal has been extremely productive, publishing more than 130 manuscripts in peer-reviewed journals. He has presented his work in multiple international meetings.
Dr. Pal began his college career at the age of 13 through the California State University, Los Angeles Early Entrance Program. He began medical school at the age of 17 at the University of California, Los Angeles (UCLA), where he developed an immediate interest in cancer research. Working in the laboratory of Dennis Slamon, M.D., Ph.D., Dr. Pal examined the breast cancer drug trastuzumab, performing laboratory-based studies to elucidate mechanisms of resistance to the agent. He continued this work during the course of his residency training at UCLA.
After completing his residency, Dr. Pal transitioned to City of Hope where he trained under Robert Figlin, M.D., developing clinical trials and translational studies for genitourinary cancer, principally in the domain of renal cell carcinoma and prostate cancer. He has garnered numerous awards to support his work, including grants from the California Breast Cancer Research Program, the National Comprehensive Cancer Network and the National Institutes of Health. He recently received a Young Investigator Award from the Kidney Cancer Association to recognize his outstanding research in this domain, and further received the 2012 Charles A. Coltman Translational Research Award from the Southwest Oncology Group to support his work in bladder cancer.
Dr. Pal’s vision is to take discoveries made in the laboratory and translate these findings as quickly and efficiently as possible into tangible benefits for patients.
Dra. Begoña Pérez Valderrama
Hospital Universitario Virgen del Rocío, Sevilla
Dr. Álvaro Pinto
Hospital Universitario La Paz, Madrid
Dr. Josep Mª Piulats
Institut Català d’Oncologia, Barcelona
Dr. Thomas Powles
Barts Cancer Institute, London, UK
Dr. Javier Puente
Hospital Universitario Clínico San Carlos, Madrid
I completed my residency in internal medicine/medical oncology at San Carlos Medical Center (Madrid, Spain). I completed a fellowship in Advanced studies graduate [DEA] & Doctoral credits in the Internal Medicine-Medical Oncology Program, Complutense University of Medicine, Madrid (Spain) between 2002-2004, also Doctoral Thesis and PhD degree (Prognostic factors in recurrent breast cancer patients), Complutense University of Medicine, Madrid (Spain) in 2007.
In 2006, I joined San Carlos Universitary Hospital´s Oncology Service. I am an attending physician and Associated Professor of Medicine Department in Complutense University, Madrid (Spain).
I am a member of the committees of the national clinical research groups SOGUG (Spanish Oncologic Genitourinary Group), GECP (Spanish Lung Cancer Group) and GETHI.
I´ve participated in multiples articles and presentations in national and international meetings, book chapters focused in oncology. Prinicipal and sub-investigator in several clinical trials in lung and genitourinary tumors.
Dr. Brian Rini
Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio
Dr. Marc Simó
Hospital Universitari de la Vall d’Hebron, Barcelona